> RESEARCH >
Induced pluripotent stem cell (iPSC) reprogramming epigenetically converts somatic cells into embryonic stem cell (ESC)-like cells, opening enormous opportunities in therapeutic applications that avoid ethical issues and immunological rejection problems. It has been used to build models of various diseases such as Parkinson disease, Huntington disease, type 1 diabetes, and spinal muscular atrophy, to regenerate cells including motor neurons and cardiomyocytes, and to test the application of such cells to the clinical treatment such as acute myocardial infarction.
Our goal is to understand the molecular mechanisms of the iPSC reprogramming process using imaging, genetics, and epigenetics assays. We are also interested in examining whether epigenetic aberrations of cancer cells can be altered or alleviated by iPSC cell reprogramming. Our current projects are:
Live-cell imaging of iPSC reprogramming process
Reprogramming of gastric cancer cells
A large circular colony of reprogrammed gastric cancer cells with clearly defined borders composed of small tightly packed cells with a high nucleus to cytoplasm ratio.